1stOncology™: Cancer Intelligence Service – Page 8795 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Precigen to Present at the JMP Securities Life Sciences Conference

On June 10, 2021 Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, reported Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat at the annual JMP Securities Life Sciences Conference on Thursday, June 17, 2021 at 11:00 AM ET (Press release, Precigen, JUN 10, 2021, View Source [SID1234583851]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Participants may access the live webcasts of the virtual events through Precigen’s website in the Events & Presentations section at investors.precigen.com/events-presentations.

Immunicom Presents Promising Clinical Trial Data at AACR in Late-Stage Breast Cancer Patients Treated with Novel Non-Pharmaceutical Immunotherapy

On June 10, 2021 Immunicom, Inc., a global biotech company reported that it is redefining immuno-oncology with breakthrough non-pharmaceutical subtractive immunotherapy treatments designed to preserve quality-of-life while being treated, presented preliminary data from its late-stage, metastatic triple-negative breast cancer (mTNBC) clinical trial at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2021 (Press release, Immunicom, JUN 10, 2021, View Source [SID1234583843]). AACR (Free AACR Whitepaper)’s Annual Meeting is one of the world’s premier scientific gatherings of cancer specialists and researchers, attracting more than 20,000 participants annually.

Immunicom is investigating its FDA-designated breakthrough Immunopheresis therapy, which is a filtration-based subtractive treatment designed to capture sTNF-R proteins that are shed by cancer cells and inhibit a patient’s natural anti-tumor immune activity. Immunicom presented data for the first cohort of mTNBC patients treated with Immunopheresis which showed an 80% decrease of the inhibitory sTNF-R proteins and observed a sustained quality-of-life while on therapy with minimal side effects.

"Current cancer treatments have significant toxicities and can dramatically diminish a patient’s quality-of-life, especially in patients with late-stage disease that have received multiple prior courses of therapy," said Amir Jafri, Immunicom CEO and Founder. "We are studying an innovative emerging therapy which could signal a new era for cancer treatment that employs a novel immunotherapeutic approach which is especially well-tolerated by these fragile patients."

Immunicom’s presentation "Extracorporeal pulldown of soluble TNFRs to unleash the activity of endogenous TNFα in chemorefractory triple-negative breast cancer patients – first-in-human experience" was presented by the study’s Chief Investigator, Piotr Wysocki, MD, PhD, Department Head of Oncology at the Jagiellonian University – Medical College Hospital in Krakow and President of the Polish Society of Clinical Oncology, and will be available online until June 21, 2021, details as follows:
View Source!/9325/presentation/5206

New AI-Based Clinical Trial Matching Solution, Deep Lens’ Viper™, Expanding Offering to Cancer Patients at Norton Healthcare

On June 10, 2021 Deep Lens reported a collaboration that will integrate Deep Lens’ artificial intelligence (AI)-based clinical trial screening and matching solution VIPER , into cancer research (Press release, Deep Lens, JUN 10, 2021, View Source [SID1234583842]). VIPER uses proprietary cloud-based technology to facilitate, triage and accelerate the clinical trial recruitment process. The technology will be used at Norton Cancer Institute, the largest provider of cancer care in the Louisville, Ky., area. VIPER will be used to streamline the patient recruitment process by minimizing resource constraints and enabling immediate access to a greater number of clinical trials.

It is estimated that more than 15,000 oncology clinical trials are actively recruiting patients; however, patient participation in these trials is often as low as three percent. The challenges associated with accrual to cancer-focused research studies are complex and have been magnified by the current global pandemic. VIPER automates the clinical trial screening process and seamlessly matches patients — at the time of diagnosis — to appropriate trials through the ingestion and analysis of customized genomic, electronic medical record and pathology data.

"Deep Lens is committed to making it easier for cancer patients to find trials that may optimize their care and potentially impact the course of their disease," said Greg Andreola, chief revenue officer for Deep Lens. "We are confident that VIPER will help reinforce Norton Cancer Institute’s prominent reputation in Kentucky and Southern Indiana and we look forward to bringing more opportunities for patients to receive access to cutting-edge therapies in development."

Deep Lens’ VIPER integrates directly into electronic medical records such as Epic, molecular data feeds (Caris, Foundation, and in-house labs) and pathology feeds to automatically identify qualified patients for clinical trials. Any practice that utilizes Epic can easily integrate VIPER and all other Deep Lens screening services free of charge.

InterVenn Biosciences Announces Clinical Validation of World’s First Glycoproteomic Diagnostic Test

On June 10, 2021 InterVenn Biosciences reported it has completed clinical and analytical validation in compliance with standards set by the Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists (CAP) of GLORITM, a liquid-biopsy diagnostic test capable of differentiating between malignant and benign female pelvic tumors (Press release, InterVenn Biosciences, JUN 10, 2021, View Source [SID1234583840]). This test marks a significant milestone for InterVenn as it seeks to establish its proprietary mass-spectrometry-based, AI-powered technology as a scalable clinical platform capable of efficiently deploying glycoproteomic diagnostic tests for a range of indications.

GLORI is a laboratory-developed test (LDT) that has been validated using both retrospective patient samples and samples collected prospectively in InterVenn’s ongoing VOCAL clinical trial. Development of GLORI was advanced after compelling positive results were obtained in an interim analysis of the VOCAL trial. With an overall accuracy of 86%, GLORI outperforms all other currently available blood-based tests used to manage patients with suspected ovarian cancer.

"The company started by leveraging the decades-long work and accomplishments of its scientific co-founders, Drs. Carolyn Bertozzi and Carlito Lebrilla, and complementing them with a powerful, AI-driven data processing engine, to build a revolutionary discovery platform for analyzing the glycoproteome at unprecedented speed and scale, and, for the first time, making glycoproteomics accessible for actionable clinical research," said Erwin Estigarribia, InterVenn’s COO. "In less than three years InterVenn has successfully interrogated more than a dozen medical conditions, assayed thousands of patient blood samples, and established definitive evidence for the ubiquitous biological impact and, in parallel, for the clear clinical utility of glycoproteomics. This gave us the confidence to embark on our first prospective clinical trial, VOCAL; and the results generated, now reflected in the translational productization of data into GLORI as a fully validated LDT, are of course extremely gratifying. They are a major step forward not only for InterVenn and its platform, but also for basic and clinical science: this is the first-ever clinical glycoproteomic test and, most importantly, for women’s health, and for patients in need of better options."

"With the validation of GLORITM as the world’s first glycoproteomic LDT we have clearly demonstrated that glycoproteomics can be used to develop high-performance diagnostic solutions and that InterVenn has reached a new stage of operational maturity," said Aldo Carrascoso, InterVenn’s CEO. "We are now looking to accelerate the development of new liquid-biopsy assays in our product pipeline, including a precision-medicine test for immuno-oncology therapy, leveraging the opportunities for which GLORITM has paved the way."

The VOCAL clinical trial reached full enrollment of the targeted patient cohort in South-East Asia earlier this year, with the completion of the trial’s additional recruitment of patients in the US and Australia anticipated by the end of the year.

InterVenn has not yet announced a date for commercial availability of GLORI as it seeks to create a harmonized approach for market introduction of all products currently in its pipeline.

NiKang Therapeutics Appoints Robert Xin, M.D., Ph.D., as Chief Medical Officer

On June 10, 2021 NiKang Therapeutics Inc. ("NiKang"), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs, reported the appointment of Robert (Xiaohua) Xin, M.D., Ph.D., as Chief Medical Officer, reporting to Zhenhai Gao, Ph.D, co-founder, president, and CEO of NiKang (Press release, NiKang Therapeutics, JUN 10, 2021, View Source [SID1234583839]). As a member of the executive leadership team, Dr. Xin will oversee the global clinical development of NiKang’s pipeline and will work closely with the discovery team to prioritize drug targets and formulate strategies.

"NiKang is on the verge of rapid growth. We are thrilled to welcome Robert at this pivotal time. His successful track record in navigating all stages of clinical development will help us effectively execute our clinical development plans," said Zhenhai Gao. "His in-depth expertise in oncology drug development and strong leadership will be invaluable and instrumental to our patient-focused mission and to the transformation of NiKang into a fully-fledged drug discovery and development company."

Dr. Xin brings to NiKang more than 20 years of experience with an excellent track record of successfully developing novel oncology therapies including small molecules, therapeutic antibodies, antibody drug conjugates and immunotherapies. Previously, Dr. Xin served as SVP, head of clinical development at Turning Point Therapeutics, where he led early and late stage clinical programs for selective small molecule inhibitors for the treatment of cancer. Before Turning Point, he spent 7 years at Pfizer and had served in positions of increasing responsibilities, most recently as interim VP of oncology early clinical development. Prior to Pfizer, Dr. Xin served for 10 years at Genentech/Roche in senior leadership roles in oncology clinical development. His early career experience includes drug discovery and translational medicine at Chiron, Eli Lilly and Sugen. Dr. Xin obtained his M.D. from Zhejiang University School of Medicine in China and a Ph.D. in Cell and Molecular Physiology from the University of North Carolina at Chapel Hill School of Medicine.

"I am honored to serve as NiKang’s Chief Medical Officer. I have been incredibly impressed with the capability and productivity of NiKang’s extremely talented and passionate drug hunters. They have built an attractive portfolio of novel small molecules against hard-to-drug targets for cancer treatment. It is an exciting time at NiKang as the company is advancing multiple promising drug candidates into clinical development. I look forward to working with the team to accomplish NiKang’s mission of helping cancer patients with unmet medical needs."